Tara Arvedson is the Chief Scientific Officer at Hexagon Bio. Before joining Hexagon, Tara was an Executive Director of Research at Amgen, where she led small-molecule and large-molecule programs in Oncology, Immuno-Oncology, Inflammation, and Hematology. Notable accomplishments include starting Amgen’s KRAS G12C-targeting effort, which resulted in the first approved KRAS targeting molecule LUMAKRASTM, and leadership of Amgen’s Oncology Bispecific T-cell Engager Platform, which resulted in several clinical candidates.
Tara received her Ph.D. in Biochemistry from the California Institute of Technology and was a Damon Runyon Postdoctoral Fellow at the University of California, San Diego.